Atlas Venture Life Science Advisors LLC Sells 81,866 Shares of Kymera Therapeutics, Inc. $KYMR

Atlas Venture Life Science Advisors LLC trimmed its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 1.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 4,578,008 shares of the company’s stock after selling 81,866 shares during the quarter. Kymera Therapeutics comprises 48.3% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its largest holding. Atlas Venture Life Science Advisors LLC owned 0.06% of Kymera Therapeutics worth $381,302,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. lifted its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics during the 4th quarter worth $63,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth $73,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KYMR. BTIG Research reiterated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 25th. B. Riley Financial upped their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a report on Monday, June 29th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their target price for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Twenty analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $122.64.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares in the company, valued at approximately $79,321,592. This represents a 6.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Noah Goodman sold 3,389 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the completion of the sale, the insider owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,637,813 shares of company stock worth $390,253,404 in the last 90 days. 15.98% of the stock is owned by corporate insiders.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $110.57 on Friday. The firm’s 50 day simple moving average is $96.24 and its 200-day simple moving average is $86.55. The company has a market cap of $9.10 billion, a P/E ratio of -30.97 and a beta of 1.95. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same period in the prior year, the firm earned ($0.82) earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. On average, analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.